Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:UTHR's Cash-to-Debt is ranked higher than
95% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. NAS:UTHR: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:UTHR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.69  Med: 29.82 Max: 15951.56
Current: No Debt
0.69
15951.56
Equity-to-Asset 0.81
NAS:UTHR's Equity-to-Asset is ranked higher than
67% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:UTHR: 0.81 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:UTHR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.37  Med: 0.73 Max: 0.97
Current: 0.81
0.37
0.97
Interest Coverage 234.54
NAS:UTHR's Interest Coverage is ranked lower than
68% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:UTHR: 234.54 )
Ranked among companies with meaningful Interest Coverage only.
NAS:UTHR' s Interest Coverage Range Over the Past 10 Years
Min: 2.02  Med: 16.2 Max: 272.23
Current: 234.54
2.02
272.23
Piotroski F-Score: 5
Altman Z-Score: 10.65
Beneish M-Score: -2.63
WACC vs ROIC
10.40%
79.83%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 60.09
NAS:UTHR's Operating Margin % is ranked higher than
97% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. NAS:UTHR: 60.09 )
Ranked among companies with meaningful Operating Margin % only.
NAS:UTHR' s Operating Margin % Range Over the Past 10 Years
Min: -29.15  Med: 35.36 Max: 66.41
Current: 60.09
-29.15
66.41
Net Margin % 41.04
NAS:UTHR's Net Margin % is ranked higher than
96% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. NAS:UTHR: 41.04 )
Ranked among companies with meaningful Net Margin % only.
NAS:UTHR' s Net Margin % Range Over the Past 10 Years
Min: -17.52  Med: 22.13 Max: 44.64
Current: 41.04
-17.52
44.64
ROE % 35.41
NAS:UTHR's ROE % is ranked higher than
97% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. NAS:UTHR: 35.41 )
Ranked among companies with meaningful ROE % only.
NAS:UTHR' s ROE % Range Over the Past 10 Years
Min: -11.59  Med: 19.34 Max: 46.03
Current: 35.41
-11.59
46.03
ROA % 28.43
NAS:UTHR's ROA % is ranked higher than
98% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. NAS:UTHR: 28.43 )
Ranked among companies with meaningful ROA % only.
NAS:UTHR' s ROA % Range Over the Past 10 Years
Min: -6.75  Med: 12.09 Max: 32.03
Current: 28.43
-6.75
32.03
ROC (Joel Greenblatt) % 184.22
NAS:UTHR's ROC (Joel Greenblatt) % is ranked higher than
96% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. NAS:UTHR: 184.22 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:UTHR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -43.1  Med: 79.54 Max: 215.37
Current: 184.22
-43.1
215.37
3-Year Revenue Growth Rate 17.60
NAS:UTHR's 3-Year Revenue Growth Rate is ranked higher than
68% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. NAS:UTHR: 17.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:UTHR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 17.6  Med: 37.8 Max: 260.9
Current: 17.6
17.6
260.9
3-Year EBITDA Growth Rate 56.00
NAS:UTHR's 3-Year EBITDA Growth Rate is ranked higher than
90% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. NAS:UTHR: 56.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:UTHR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -56.2  Med: 22.7 Max: 128
Current: 56
-56.2
128
3-Year EPS without NRI Growth Rate 66.90
NAS:UTHR's 3-Year EPS without NRI Growth Rate is ranked higher than
94% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. NAS:UTHR: 66.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:UTHR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -50.7  Med: 19.7 Max: 153.6
Current: 66.9
-50.7
153.6
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:UTHR's 10-Y Financials

Financials (Next Earnings Date: 2017-07-26 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

UTHR Guru Trades in Q2 2016

David Dreman 2,670 sh (+2036.00%)
Lee Ainslie 26,710 sh (+27.62%)
Joel Greenblatt 367,075 sh (+1.24%)
Ken Fisher 3,092 sh (unchged)
Jim Simons 404,300 sh (-14.81%)
Paul Tudor Jones 3,700 sh (-19.57%)
Ray Dalio 64,100 sh (-25.32%)
» More
Q3 2016

UTHR Guru Trades in Q3 2016

Paul Tudor Jones 10,104 sh (+173.08%)
Ray Dalio 113,805 sh (+77.54%)
Ken Fisher 3,124 sh (+1.03%)
David Dreman 2,670 sh (unchged)
Lee Ainslie 25,910 sh (-3.00%)
Jim Simons 390,100 sh (-3.51%)
Joel Greenblatt 317,358 sh (-13.54%)
» More
Q4 2016

UTHR Guru Trades in Q4 2016

Jim Simons 421,200 sh (+7.97%)
Lee Ainslie 26,210 sh (+1.16%)
Ken Fisher 3,124 sh (unchged)
Joel Greenblatt 166,025 sh (-47.69%)
Ray Dalio 43,905 sh (-61.42%)
Paul Tudor Jones 3,534 sh (-65.02%)
David Dreman 146 sh (-94.53%)
» More
Q1 2017

UTHR Guru Trades in Q1 2017

Ken Fisher 3,124 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with UTHR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:IONS, OTCPK:SBMFF, NAS:BIVV, NAS:EXEL, NAS:NBIX, NAS:ARIA, NAS:ALNY, NAS:KITE, NAS:ACAD, NAS:GLPG, NAS:TECH, NAS:BLUE, NAS:TSRO, OTCPK:BTGGF, NAS:CBPO, NAS:NKTR, NAS:ICPT, NAS:RARE, NAS:SAGE, NAS:JUNO » details
Traded in other countries:UTH.Germany,
Headquarter Location:USA
United Therapeutics Corp is a biotechnology company. The Company is engaged in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The firm is a market leader in two of the three primary drugs classes used to treat PAH. Nearly all of its sales are generated within the U.S. United also markets a pediatric oncology drug.

Top Ranked Articles about United Therapeutics Corp

Gurus Invest in Top Biotechnology Stocks Graham’s Lost Formula unearths biotech gem; many guru buys occur
Throughout the first quarter, many gurus have increased their positions in top-performing biotechnology stocks, suggesting that the biotechnology sector contains some hot opportunities to increase portfolio returns. One of the hottest biotech stocks, United Therapeutics Corp. (NASDAQ:UTHR), is currently owned by seven gurus. Additionally, four gurus increased their position in United Therapeutics, one of eight biotechnology stocks listed on the Ben Graham’s Lost Formula I Screener. Read more...

Ratios

vs
industry
vs
history
PE Ratio 8.81
UTHR's PE Ratio is ranked higher than
90% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 28.38 vs. UTHR: 8.81 )
Ranked among companies with meaningful PE Ratio only.
UTHR' s PE Ratio Range Over the Past 10 Years
Min: 4.95  Med: 21.57 Max: 171.34
Current: 8.81
4.95
171.34
Forward PE Ratio 8.30
UTHR's Forward PE Ratio is ranked higher than
92% of the 160 Companies
in the Global Biotechnology industry.

( Industry Median: 18.05 vs. UTHR: 8.30 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 8.81
UTHR's PE Ratio without NRI is ranked higher than
91% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 29.63 vs. UTHR: 8.81 )
Ranked among companies with meaningful PE Ratio without NRI only.
UTHR' s PE Ratio without NRI Range Over the Past 10 Years
Min: 4.95  Med: 21.42 Max: 171.34
Current: 8.81
4.95
171.34
Price-to-Owner-Earnings 10.18
UTHR's Price-to-Owner-Earnings is ranked higher than
81% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. UTHR: 10.18 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
UTHR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.08  Med: 35.11 Max: 570.89
Current: 10.18
5.08
570.89
PB Ratio 2.74
UTHR's PB Ratio is ranked higher than
57% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. UTHR: 2.74 )
Ranked among companies with meaningful PB Ratio only.
UTHR' s PB Ratio Range Over the Past 10 Years
Min: 2.01  Med: 3.83 Max: 10.39
Current: 2.74
2.01
10.39
PS Ratio 3.65
UTHR's PS Ratio is ranked higher than
75% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. UTHR: 3.65 )
Ranked among companies with meaningful PS Ratio only.
UTHR' s PS Ratio Range Over the Past 10 Years
Min: 2.88  Med: 5.5 Max: 11.73
Current: 3.65
2.88
11.73
Price-to-Free-Cash-Flow 8.34
UTHR's Price-to-Free-Cash-Flow is ranked higher than
80% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. UTHR: 8.34 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
UTHR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.02  Med: 19.51 Max: 618.25
Current: 8.34
8.02
618.25
Price-to-Operating-Cash-Flow 7.78
UTHR's Price-to-Operating-Cash-Flow is ranked higher than
81% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. UTHR: 7.78 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
UTHR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.49  Med: 17.17 Max: 46.12
Current: 7.78
7.49
46.12
EV-to-EBIT 4.68
UTHR's EV-to-EBIT is ranked higher than
83% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. UTHR: 4.68 )
Ranked among companies with meaningful EV-to-EBIT only.
UTHR' s EV-to-EBIT Range Over the Past 10 Years
Min: -31.2  Med: 12 Max: 120.9
Current: 4.68
-31.2
120.9
EV-to-EBITDA 4.53
UTHR's EV-to-EBITDA is ranked higher than
83% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. UTHR: 4.53 )
Ranked among companies with meaningful EV-to-EBITDA only.
UTHR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -33.7  Med: 11.3 Max: 102.2
Current: 4.53
-33.7
102.2
PEG Ratio 0.26
UTHR's PEG Ratio is ranked higher than
94% of the 101 Companies
in the Global Biotechnology industry.

( Industry Median: 2.13 vs. UTHR: 0.26 )
Ranked among companies with meaningful PEG Ratio only.
UTHR' s PEG Ratio Range Over the Past 10 Years
Min: 0.15  Med: 0.39 Max: 2.43
Current: 0.26
0.15
2.43
Shiller PE Ratio 23.26
UTHR's Shiller PE Ratio is ranked higher than
81% of the 53 Companies
in the Global Biotechnology industry.

( Industry Median: 53.05 vs. UTHR: 23.26 )
Ranked among companies with meaningful Shiller PE Ratio only.
UTHR' s Shiller PE Ratio Range Over the Past 10 Years
Min: 22.4  Med: 48.06 Max: 679.13
Current: 23.26
22.4
679.13
Current Ratio 3.52
UTHR's Current Ratio is ranked higher than
52% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. UTHR: 3.52 )
Ranked among companies with meaningful Current Ratio only.
UTHR' s Current Ratio Range Over the Past 10 Years
Min: 0.96  Med: 5.16 Max: 64.22
Current: 3.52
0.96
64.22
Quick Ratio 3.27
UTHR's Quick Ratio is ranked higher than
51% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. UTHR: 3.27 )
Ranked among companies with meaningful Quick Ratio only.
UTHR' s Quick Ratio Range Over the Past 10 Years
Min: 0.9  Med: 4.91 Max: 64.22
Current: 3.27
0.9
64.22
Days Inventory 402.64
UTHR's Days Inventory is ranked lower than
93% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. UTHR: 402.64 )
Ranked among companies with meaningful Days Inventory only.
UTHR' s Days Inventory Range Over the Past 10 Years
Min: 118.32  Med: 167.09 Max: 455.12
Current: 402.64
118.32
455.12
Days Sales Outstanding 42.88
UTHR's Days Sales Outstanding is ranked higher than
61% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. UTHR: 42.88 )
Ranked among companies with meaningful Days Sales Outstanding only.
UTHR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.71  Med: 45.68 Max: 49.96
Current: 42.88
36.71
49.96
Days Payable 34.26
UTHR's Days Payable is ranked lower than
62% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. UTHR: 34.26 )
Ranked among companies with meaningful Days Payable only.
UTHR' s Days Payable Range Over the Past 10 Years
Min: 18.67  Med: 40.17 Max: 246.85
Current: 34.26
18.67
246.85

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 5.60
UTHR's 3-Year Average Share Buyback Ratio is ranked higher than
99% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. UTHR: 5.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
UTHR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -9.9  Med: -0.85 Max: 5.6
Current: 5.6
-9.9
5.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 8.57
UTHR's Price-to-Net-Cash is ranked lower than
66% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. UTHR: 8.57 )
Ranked among companies with meaningful Price-to-Net-Cash only.
UTHR' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.51  Med: 10.1 Max: 160.03
Current: 8.57
1.51
160.03
Price-to-Net-Current-Asset-Value 5.62
UTHR's Price-to-Net-Current-Asset-Value is ranked higher than
51% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. UTHR: 5.62 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
UTHR' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.46  Med: 10.26 Max: 5533
Current: 5.62
1.46
5533
Price-to-Tangible-Book 2.79
UTHR's Price-to-Tangible-Book is ranked higher than
64% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. UTHR: 2.79 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
UTHR' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.16  Med: 3.66 Max: 18.16
Current: 2.79
1.16
18.16
Price-to-Intrinsic-Value-Projected-FCF 0.81
UTHR's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
86% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. UTHR: 0.81 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
UTHR' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.81  Med: 2.73 Max: 232.67
Current: 0.81
0.81
232.67
Price-to-Median-PS-Value 0.67
UTHR's Price-to-Median-PS-Value is ranked higher than
70% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. UTHR: 0.67 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
UTHR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.57  Med: 1.43 Max: 288.8
Current: 0.67
0.57
288.8
Price-to-Peter-Lynch-Fair-Value 0.35
UTHR's Price-to-Peter-Lynch-Fair-Value is ranked higher than
97% of the 66 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. UTHR: 0.35 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
UTHR' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.21  Med: 0.99 Max: 5.82
Current: 0.35
0.21
5.82
Price-to-Graham-Number 1.05
UTHR's Price-to-Graham-Number is ranked higher than
82% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 2.64 vs. UTHR: 1.05 )
Ranked among companies with meaningful Price-to-Graham-Number only.
UTHR' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.77  Med: 2.48 Max: 6.18
Current: 1.05
0.77
6.18
Earnings Yield (Greenblatt) % 21.37
UTHR's Earnings Yield (Greenblatt) % is ranked higher than
94% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. UTHR: 21.37 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
UTHR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.8  Med: 6.8 Max: 40.2
Current: 21.37
0.8
40.2
Forward Rate of Return (Yacktman) % 38.58
UTHR's Forward Rate of Return (Yacktman) % is ranked higher than
86% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 16.45 vs. UTHR: 38.58 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
UTHR' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -1.4  Med: 1.4 Max: 56.9
Current: 38.58
-1.4
56.9

More Statistics

Revenue (TTM) (Mil) $1,600
EPS (TTM) $ 14.27
Beta1.35
Short Percentage of Float13.93%
52-Week Range $97.52 - 169.89
Shares Outstanding (Mil)45.06

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,680 1,505 1,349
EPS ($) 14.93 13.53 11.23
EPS without NRI ($) 14.93 13.53 11.23
EPS Growth Rate
(Future 3Y To 5Y Estimate)
-6.70%
Dividends per Share ($)
» More Articles for UTHR

Headlines

Articles On GuruFocus.com
United Therapeutics Announces $250 Million Share Repurchase Program Apr 27 2017 
United Therapeutics Corporation Reports First Quarter 2017 Financial Results Apr 26 2017 
3D Systems and United Therapeutics Announce Bioprinting Agreement Apr 26 2017 
United Therapeutics Corporation To Report First Quarter 2017 Financial Results Before The Market Ope Apr 19 2017 
United Therapeutics Announces Regulatory Delays For Remosynch Implantable Pump Apr 03 2017 
United Therapeutics Announces Decision From Patent Trial And Appeal Board And Issuance Of New Patent Mar 31 2017 
Gurus Invest in Undervalued Biotech Stocks Nov 25 2016 
6 Undervalued Stocks Trading Below the Peter Lynch Value Oct 26 2016 
These Five Stocks Show a Combination of Value and Growth Aug 03 2016 
Worst Performance YTD: MasterCard, Lazard Aug 03 2016 

More From Other Websites
United Therapeutics' Martine Rothblatt saw pay jump last year in midst of executive shakeup Apr 28 2017
United Therapeutics partners with 3-D printer to make human organs Apr 28 2017
Edited Transcript of UTHR earnings conference call or presentation 26-Apr-17 1:00pm GMT Apr 28 2017
United Therapeutics Announces $250 Million Share Repurchase Program Apr 27 2017
United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss Apr 27 2017
Blog Coverage3D Systems and United Therapeutics Partner to Develop 3D Bioprinted Lungs Apr 27 2017
These Greater Washington companies may be most affected by Trump's tax reform Apr 26 2017
3D Systems signs 'bioprinting' agreement to eventually create human organs Apr 26 2017
United Therapeutics beats 1Q profit forecasts Apr 26 2017
United Therapeutics Corporation Reports First Quarter 2017 Financial Results Apr 26 2017
3D Systems and United Therapeutics Announce Bioprinting Agreement Apr 26 2017
Drug Stocks Q1 Earnings Releases on Apr 26: AMGN, GSK & More Apr 25 2017
Rising Revenue and Earnings: Mistubishi Financial, United Therapeutics Apr 19 2017
United Therapeutics Corporation To Report First Quarter 2017 Financial Results Before The Market... Apr 19 2017
PolarityTE(TM), Inc. Recruits Key Additions to Management Apr 18 2017
5 Major Drug Stocks Likely to Beat Q1 Earnings Estimates Apr 17 2017
Company News for April 04, 2017 Apr 04 2017
United Therapeutics Tanks, Remodulin Pump Launch Delayed Apr 04 2017
Why DryShips, United Therapeutics, and Fiat Chrysler Automobiles Slumped Today Apr 03 2017
SteadyMed Wins Patent Challenge Vs United Therapeutics Apr 03 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)